Have you ever glanced at the passenger-side mirror and noticed the message written on it? Objects are closer than they appear. The mirror makes objects appear farther away than they actually are. That warning summarizes my week. When I was diagnosed with idiopathic pulmonary fibrosis in January 2017,…
Advocates shine a light on living life with PF this awareness month
My husband, Donnie, and I and our children just returned from a family vacation. We had a wonderful time, but I wish I’d done more research beforehand to make things a little easier. While I always feel like we do a fair amount of planning, once we’re away, there are…
The U.S. Food and Drug Administration (FDA) has given fast track designation to LTI-03, an inhaled therapy candidate that Rein Therapeutics is developing for idiopathic pulmonary fibrosis (IPF). Fast track status is intended to facilitate the development and review of drugs that treat serious conditions and address unmet…
Note: This column describes the author’s own experiences with various medications. Not everyone will have the same response to treatment. Consult your doctor before starting or stopping a therapy. What do you do while you wait for your current condition to improve? Over the past couple of weeks, I’ve noticed…
A new type of pericyte called Peri2 is linked to scar tissue formation in the lungs of people with pulmonary fibrosis (PF), according to a study. Pericytes are cells that surround blood vessels. A gene called FOXF1 was also shown to help control whether these cells stay healthy or…
In case you hadn’t noticed, I didn’t file a column last week. I missed you and feel like I need to explain. My body told me I needed to take a break. I had back-to-back medical appointments that left me wiped out, so I decided to listen to my body.
According to its U.S. developer, the first of two global clinical trials designed to test Haduvio (nalbuphine extended-release) — a potential treatment for chronic cough due to idiopathic pulmonary fibrosis (IPF) — is now underway, with the second expected to launch later this year. The initial Phase 3 trial,…
The inhaled therapy MNKD-201 was tolerated well in people with idiopathic pulmonary fibrosis (IPF) in a Phase 1 clinical trial, and a Phase 2 study to further test it is underway, the treatment’s developer said. The Phase 2 trial, INFLO-2 (NCT07679893), aims to enroll more than 200 adults…
Idiopathic pulmonary fibrosis (IPF) is emerging as a “hot spot” for drug development research, according to the nonprofit CheckOrphan, which notes that “investor and industry interest is accelerating.” A May 2026 article on the organization’s website notes recent activity by Avalyn Pharma, which has secured $100 million in…
